CD38 Deficiency Alleviates Diabetic Cardiomyopathy by Coordinately Inhibiting Pyroptosis and Apoptosis

Ling-Fang Wang1, Qian Li1, Ke Wen1

  • 1National Engineering Research Center for Bioengineering Drugs and the Technologies, Institute of Translational Medicine, Nanchang University, Nanchang 330031, China.

Insights

CD38 deficiency prevents diabetic cardiomyopathy by reducing cell death through the NAD+/Sirt3/FOXO3a pathway. This finding offers a potential therapeutic target for managing heart complications in diabetes mellitus.

Area of Science:

  • Cardiovascular Biology
  • Metabolic Diseases
  • Molecular Medicine

Background:

  • Diabetic cardiomyopathy, a complication of diabetes mellitus, leads to heart failure.
  • CD38, an NAD+ hydrolase, is implicated in cardiovascular diseases, but its role in diabetic cardiomyopathy is unclear.

Purpose of the Study:

  • To investigate the role of CD38 in the development of diabetic cardiomyopathy.
  • To explore the therapeutic potential of CD38 deficiency in mitigating diabetes-induced heart damage.

Main Methods:

  • Utilized CD38 knockout (CD38-KO) mice subjected to a high-fat diet and streptozotocin (STZ) injection.
  • Assessed cardiac function, cardiomyocyte apoptosis, pyroptosis, and molecular signaling pathways (NAD+/Sirt3/FOXO3a).

Main Results:

  • CD38 deficiency significantly protected against diabetic cardiomyopathy, improving cardiac function (ejection fraction, fractional shortening).
  • CD38 deficiency reduced cardiomyocyte apoptosis and pyroptosis induced by diabetes or high glucose/palmitic acid.
  • Upregulated CD38 and downregulated Sirt3 were observed in diabetic mouse hearts; CD38 deficiency increased Sirt3 and FOXO3a expression.

Conclusions:

  • CD38 deficiency ameliorates diabetic cardiomyopathy by inhibiting apoptosis and pyroptosis.
  • The protective effect is mediated through the activation of the NAD+/Sirt3/FOXO3a signaling pathway.